查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088242

人工智慧在藥物研發領域的市場：按技術、治療領域、應用、最終用戶和部署模式分類——2026-2032年全球市場預測

Artificial Intelligence in Drug Discovery Market by Technology, Therapeutic Area, Application, End User, Deployment Mode - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人工智慧 (AI) 在藥物發現領域的市場規模將達到 67.1 億美元，複合年成長率為 18.12%。

主要市場統計數據
基準年 2025 20.9億美元
預計年份：2026年 24.6億美元
預測年份 2032 67.1億美元
複合年成長率 (%) 18.12%

人工智慧在藥物研發領域的應用正從實驗性應用轉向核心研發能力，涵蓋標靶辨識、先導化合物發現、先導化合物最佳化、ADMET預測、生物標記發現和臨床試驗設計。這項轉變得到了許多已證實的科學里程碑的支持，例如：包含超過2億個預測蛋白質結構的AlphaFold蛋白質結構資料庫；美國FDA對人工智慧和機器學習在藥物研發領域持續投入的承諾；以及高性能雲端運算在生命科學領域的日益廣泛的應用。

對於製藥公司、生物技術公司、受託研究機構(CRO) 和技術合作夥伴而言，人工智慧並非旨在取代生物學、化學或臨床證據。其最大價值在於縮短假設檢驗週期、提高決策質量，並在進行高成本的實驗室研究或臨床投資之前，優先考慮化合物和患者群體。

人工智慧在藥物發現領域帶來的變革

藥物發現的格局正在從以實驗室為中心的順序式工作流程轉向整合式計算和實驗模型。生成式人工智慧、圖神經網路、自然語言處理和多模態基礎模型正在幫助研究人員大規模分析化學庫、組體學資料集、蛋白質結構、學術論文、專利和真實世界資料。

人工智慧對藥物發現研究和開發的累積影響

人工智慧的累積影響在早期階段的實證決策中最為顯著。人工智慧平台可以幫助識別疾病相關標靶、篩檢虛擬化合物庫、預測毒性、最佳化分子特性以及對患者進行分層。這些應用減少了不必要的實驗，並提高了進入檢驗階段的候選化合物的品質。

主要區域洞察：北美、歐洲、亞太、拉丁美洲、中東和非洲

北美在人工智慧驅動的藥物研發領域處於領先地位，這得益於製藥公司、人工智慧生物技術公司、大學醫療中心、雲端服務供應商、創業投資公司和監管機構之間緊密的合作生態系統。美國受益於國立衛生研究院 (NIH) 資助的生物醫學研究、美國食品藥物管理局 (FDA) 的數位健康和​​人工智慧計劃，以及大規模的臨床試驗基礎設施。同時，加拿大在人工智慧研究和食品藥物管理局叢集長期累積的優勢，正在推動轉化創新。

來自主要組織（歐盟、七國集團、金磚國家、東協、海灣合作理事會、北約）的見解

歐盟憑藉其先進的研究網路和嚴格的資料保護、臨床證據和演算法課責規則，正逐漸成為生命科學領域可靠人工智慧的市場。七國集團（G7）成員國透過其在製藥領域的強勁研發投入、卓越的學術成就、完善的智慧財產權體系、協調監管科學以​​及在衛生安全方面的跨國合作，持續引領全球標準的發展。

對主要人工智慧藥物發現市場關鍵國家的洞察

美國仍然是人工智慧藥物研發領域最具影響力的國家，這得益於其集中的製藥研發力量、創業投資投資支持的人工智慧生物技術公司、與美國食品藥物管理局（FDA）的合作、美國國立衛生研究院（NIH）支持的生物醫學研究以及世界一流的學術醫療中心。加拿大擁有世界一流的機器學習技術和轉化人工智慧中心，而墨西哥和巴西則透過臨床研究、藥物生產能力​​、公共衛生機構以及數位醫療的日益普及，正在加強美洲在該領域的基礎建設。

為行業領導者提供的實用建議

產業領導者應優先考慮那些能夠衡量其科學和營運價值的人工智慧應用案例，例如標靶檢驗、虛擬篩檢、毒性預測、蛋白質結構分析、生物標記發現以及提升臨床試驗品質。建立競爭優勢需要專有資料集、可互通的資料架構、模型檢驗方案、偏差監控、網路安全措施以及符合監管要求的清晰文件。

調查方法

本執行摘要基於系統的二手研究途徑，使用了來自監管機構、科研機構、政府項目、同行評審文獻、公共資訊和權威生命科學資料庫的檢驗公開資訊。我們從多個角度檢驗了關鍵主題，包括人工智慧驅動的藥物發現工作流程、區域創新體系、監管趨勢、科學領域的應用以及投資模式。

結論：人工智慧作為現代藥物研發的戰略引擎

人工智慧正逐漸成為藥物研發領域的永續能力，它能夠提高科學決策的速度、規模和準確性。當計算模型與可靠的生物學數據、實驗室檢驗、臨床見解和嚴格的管治相結合時，其最大價值才能得以實現。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：人工智慧在藥物研發領域的市場：依技術分類

  • 電腦視覺
  • 深度學習
  • 機器學習
  • 自然語言處理

第8章：人工智慧在藥物研發領域的市場：依治療領域分類

  • 心血管疾病
  • 中樞神經系統
  • 感染疾病
  • 腫瘤學

第9章：人工智慧在藥物發現領域的市場：按應用分類

  • ADMET和毒性預測
    • 動態預測
    • 藥物動力學預測
    • 毒性預測
  • 臨床試驗的最佳化
    • 招募測試對象
    • 測試設計最佳化
  • 命中識別
    • 高通量篩檢
    • In Silico標靶檢驗
    • 虛擬篩檢
  • 先導藥物最適化
    • 德諾和製藥
    • 定量構效關係
    • 基於結構的藥物發現
  • 蛋白質結構預測
    • 第一原理建模
    • 同源建模
    • 分子動力學模擬

第10章：人工智慧在藥物發現領域的市場：以最終用戶分類

  • 學術研究機構
  • 生技公司
  • 受託研究機構
  • 製藥公司

第11章：人工智慧在藥物發現領域的市場：依部署模式分類

  • 基於雲端的
  • 混合
  • 現場

第12章：人工智慧在藥物研發領域的市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：人工智慧在藥物研發領域的市場：按群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：人工智慧在藥物研發領域的市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbCellera
  • Atomwise Inc
  • BenchSci
  • BenevolentAI
  • BioAge Labs
  • Bpgbio Inc
  • Deep Genomics
  • Envisagenics
  • Evaxion Biotech A/S
  • Generate Biomedicines
  • Genesis Therapeutics
  • Iambic Therapeutics
  • Iktos
  • Insilico Medicine
  • Insitro
  • Nimbus Therapeutics
  • NuMedii Inc
  • Owkin Inc
  • Recursion Pharmaceuticals
  • Schrodinger Inc
  • Standigm Inc
  • Terray Therapeutics
  • Valo Health
  • Verge Genomics
  • XtalPi Inc
Product Code: MRR-031BF22F953D

The Artificial Intelligence in Drug Discovery Market is projected to grow by USD 6.71 billion at a CAGR of 18.12% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.09 billion
Estimated Year [2026] USD 2.46 billion
Forecast Year [2032] USD 6.71 billion
CAGR (%) 18.12%

Artificial intelligence in drug discovery has moved from experimental use cases to a core R&D capability across target identification, hit discovery, lead optimization, ADMET prediction, biomarker discovery, and clinical trial design. The shift is supported by validated scientific milestones, including the AlphaFold Protein Structure Database covering more than 200 million predicted protein structures, the U.S. FDA's ongoing work on AI and machine learning in drug development, and the growing use of high-performance cloud computing in life sciences.

For pharmaceutical companies, biotechnology firms, contract research organizations, and technology partners, AI is not a replacement for biology, chemistry, or clinical evidence. Its strongest value is in compressing hypothesis cycles, improving decision quality, and prioritizing compounds and patient populations before expensive wet-lab or clinical investments are made.

Transformative Shifts in the AI Drug Discovery Landscape

The drug discovery landscape is shifting from sequential, lab-intensive workflows to integrated computational-experimental models. Generative AI, graph neural networks, natural language processing, and multimodal foundation models are helping researchers analyze chemical libraries, omics datasets, protein structures, publications, patents, and real-world data at scale.

Regulatory and operating models are also changing. The U.S. FDA, EMA, and other agencies are increasing attention on model transparency, validation, data provenance, and risk management. At the same time, cloud infrastructure, secure data collaboration, and automation are enabling pharmaceutical R&D teams to evaluate more hypotheses while maintaining traceability and reproducibility.

Cumulative Impact of Artificial Intelligence on Drug R&D

The cumulative impact of artificial intelligence is most visible in earlier and more evidence-driven decision-making. AI-enabled platforms can help identify disease-relevant targets, screen virtual compound libraries, forecast toxicity, optimize molecular properties, and support patient stratification. These applications reduce avoidable experimentation and improve the quality of candidates moving into validation.

However, AI does not eliminate scientific uncertainty. Drug attrition remains driven by complex biology, safety, efficacy, manufacturability, and clinical execution. The organizations gaining the greatest advantage are those combining high-quality proprietary data, rigorous model governance, laboratory validation, and cross-functional teams spanning biology, chemistry, informatics, clinical development, and regulatory affairs.

Key Regional Insights: North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa

North America leads AI-enabled drug discovery through a dense ecosystem of pharmaceutical companies, AI-native biotechnology firms, academic medical centers, cloud providers, venture capital, and regulatory engagement. The United States benefits from NIH-funded biomedical research, FDA digital health and AI initiatives, and a large clinical trial infrastructure, while Canada's long-standing AI research base and biomedical clusters strengthen translational innovation.

Europe is advancing through strong public research, biopharmaceutical manufacturing, and regulatory modernization, including the EU AI Act and European Health Data Space framework. Asia-Pacific is scaling rapidly, with China, Japan, India, South Korea, Singapore, and Australia investing in genomics, precision medicine, computational biology, and biomanufacturing. Latin America is emerging through Brazil and Mexico's clinical research capacity, public health datasets, and pharmaceutical manufacturing foundations, while the Middle East is investing in genomics, digital health, and precision medicine through national strategies in the UAE, Saudi Arabia, and other Gulf economies. Africa's opportunity is tied to genomic diversity, infectious disease research, local biobank development, and capacity-building programs that can improve global model generalizability and reduce data bias in AI drug discovery.

Key Group Insights: EU, G7, BRICS, ASEAN, GCC, and NATO

The European Union is becoming a reference market for trustworthy AI in life sciences, combining advanced research networks with strict rules on data protection, clinical evidence, and algorithmic accountability. G7 countries continue to shape global standards through pharmaceutical R&D intensity, academic excellence, intellectual property systems, regulatory science coordination, and cross-border collaboration on health security.

BRICS economies are strategically important because of their population scale, expanding clinical research networks, manufacturing capacity, and increasing investment in AI, genomics, and biotechnology. ASEAN is gaining relevance through Singapore-led biomedical innovation, regional digital health adoption, and growing clinical research activity across Southeast Asia, while the GCC is using national health transformation programs, population genomics initiatives, and advanced hospital infrastructure to accelerate precision medicine. NATO member countries also influence the sector indirectly through biosecurity, resilient supply chains, cybersecurity, trusted data infrastructure, and dual-use technology governance that affect AI-enabled biomedical innovation.

Key Country Insights Across Major AI Drug Discovery Markets

The United States remains the most influential country for AI in drug discovery due to its concentration of pharmaceutical R&D, venture-backed AI biotechnology companies, FDA engagement, NIH-supported biomedical research, and leading academic medical centers. Canada contributes world-class machine learning expertise and translational AI hubs, while Mexico and Brazil strengthen the Americas through clinical research access, pharmaceutical production capabilities, public health institutions, and growing digital health adoption.

In Europe, the United Kingdom combines biomedical research excellence, national health data assets, and a strong AI startup ecosystem; Germany leads in pharmaceutical manufacturing, engineering, applied research, and industrial automation; France supports AI and health innovation through national investment programs and biomedical research networks; Italy and Spain offer strong clinical trial networks, hospital systems, and translational medicine capabilities; and Russia retains scientific capacity in chemistry, mathematics, and computational research despite geopolitical and collaboration constraints. In Asia-Pacific, China's scale in data infrastructure, AI investment, genomics, and biopharma innovation is significant; India combines pharmaceutical manufacturing, digital public infrastructure, bioinformatics talent, and software engineering depth; Japan offers advanced precision medicine, robotics, and aging-related biomedical research capabilities; Australia has strong clinical research, genomics programs, and biomedical science institutions; and South Korea is expanding rapidly through government-backed biohealth, hospital digitalization, semiconductor strength, and AI initiatives.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize AI use cases with measurable scientific and operational value, such as target validation, virtual screening, toxicity prediction, protein structure analysis, biomarker discovery, and trial enrichment. Building a defensible advantage requires proprietary datasets, interoperable data architecture, model validation protocols, bias monitoring, cybersecurity controls, and clear documentation aligned with regulatory expectations.

Should also invest in human-AI operating models. The highest-performing organizations embed computational scientists with medicinal chemists, biologists, clinicians, and regulatory experts. Partnerships with AI biotechnology firms, cloud providers, universities, and CROs should be structured around data rights, reproducibility, auditability, model ownership, privacy protection, and milestone-based outcomes rather than technology adoption alone.

Research Methodology

This executive summary is based on a structured secondary research approach using verified public information from regulatory agencies, scientific institutions, government programs, peer-reviewed literature, public disclosures, and recognized life sciences databases. Key themes were triangulated across AI drug discovery workflows, regional innovation systems, regulatory developments, scientific adoption, and investment patterns.

The analysis emphasizes evidence-backed trends rather than speculative market claims. It evaluates how artificial intelligence is applied across discovery and development, where adoption is strongest, which regional ecosystems are gaining momentum, and what governance practices are needed to convert computational insights into validated therapeutic progress.

Conclusion: AI as a Strategic Engine for Modern Drug Discovery

Artificial intelligence is becoming a durable capability in drug discovery because it improves the speed, scale, and precision of scientific decision-making. Its greatest value is achieved when computational models are connected to reliable biological data, laboratory validation, clinical insight, and disciplined governance.

The landscape will be shaped by organizations that can combine AI innovation with regulatory credibility, proprietary data, and therapeutic domain expertise. As adoption expands across regions and industry groups, AI-enabled drug discovery is expected to remain one of the most important forces modernizing pharmaceutical R&D.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Artificial Intelligence in Drug Discovery Market, by Technology

  • 7.1. Computer Vision
  • 7.2. Deep Learning
  • 7.3. Machine Learning
  • 7.4. Natural Language Processing

8. Artificial Intelligence in Drug Discovery Market, by Therapeutic Area

  • 8.1. Cardiovascular Diseases
  • 8.2. Central Nervous System
  • 8.3. Infectious Diseases
  • 8.4. Oncology

9. Artificial Intelligence in Drug Discovery Market, by Application

  • 9.1. ADMET & Toxicology Prediction
    • 9.1.1. Pharmacodynamics Prediction
    • 9.1.2. Pharmacokinetics Prediction
    • 9.1.3. Toxicity Prediction
  • 9.2. Clinical Trial Optimization
    • 9.2.1. Patient Recruitment
    • 9.2.2. Trial Design Optimization
  • 9.3. Hit Identification
    • 9.3.1. High Throughput Screening
    • 9.3.2. In Silico Target Validation
    • 9.3.3. Virtual Screening
  • 9.4. Lead Optimization
    • 9.4.1. De Novo Drug Design
    • 9.4.2. Quantitative Structure Activity Relationship
    • 9.4.3. Structure Based Drug Design
  • 9.5. Protein Structure Prediction
    • 9.5.1. Ab Initio Modeling
    • 9.5.2. Homology Modeling
    • 9.5.3. Molecular Dynamics Simulation

10. Artificial Intelligence in Drug Discovery Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Biotechnology Companies
  • 10.3. Contract Research Organizations
  • 10.4. Pharmaceutical Companies

11. Artificial Intelligence in Drug Discovery Market, by Deployment Mode

  • 11.1. Cloud Based
  • 11.2. Hybrid
  • 11.3. On Premises

12. Artificial Intelligence in Drug Discovery Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Artificial Intelligence in Drug Discovery Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Artificial Intelligence in Drug Discovery Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbCellera
  • 16.2. Atomwise Inc
  • 16.3. BenchSci
  • 16.4. BenevolentAI
  • 16.5. BioAge Labs
  • 16.6. Bpgbio Inc
  • 16.7. Deep Genomics
  • 16.8. Envisagenics
  • 16.9. Evaxion Biotech A/S
  • 16.10. Generate Biomedicines
  • 16.11. Genesis Therapeutics
  • 16.12. Iambic Therapeutics
  • 16.13. Iktos
  • 16.14. Insilico Medicine
  • 16.15. Insitro
  • 16.16. Nimbus Therapeutics
  • 16.17. NuMedii Inc
  • 16.18. Owkin Inc
  • 16.19. Recursion Pharmaceuticals
  • 16.20. Schrodinger Inc
  • 16.21. Standigm Inc
  • 16.22. Terray Therapeutics
  • 16.23. Valo Health
  • 16.24. Verge Genomics
  • 16.25. XtalPi Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPUTER VISION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPUTER VISION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPUTER VISION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DEEP LEARNING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DEEP LEARNING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DEEP LEARNING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MACHINE LEARNING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MACHINE LEARNING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MACHINE LEARNING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NATURAL LANGUAGE PROCESSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NATURAL LANGUAGE PROCESSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NATURAL LANGUAGE PROCESSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADMET & TOXICOLOGY PREDICTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADMET & TOXICOLOGY PREDICTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADMET & TOXICOLOGY PREDICTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACODYNAMICS PREDICTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACODYNAMICS PREDICTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACODYNAMICS PREDICTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACOKINETICS PREDICTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACOKINETICS PREDICTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACOKINETICS PREDICTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TOXICITY PREDICTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TOXICITY PREDICTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TOXICITY PREDICTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CLINICAL TRIAL OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CLINICAL TRIAL OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CLINICAL TRIAL OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PATIENT RECRUITMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PATIENT RECRUITMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PATIENT RECRUITMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRIAL DESIGN OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRIAL DESIGN OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRIAL DESIGN OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HIT IDENTIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HIT IDENTIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HIT IDENTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IN SILICO TARGET VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN SILICO TARGET VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IN SILICO TARGET VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VIRTUAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VIRTUAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VIRTUAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DE NOVO DRUG DESIGN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DE NOVO DRUG DESIGN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DE NOVO DRUG DESIGN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL STRUCTURE BASED DRUG DESIGN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL STRUCTURE BASED DRUG DESIGN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL STRUCTURE BASED DRUG DESIGN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PROTEIN STRUCTURE PREDICTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROTEIN STRUCTURE PREDICTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PROTEIN STRUCTURE PREDICTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AB INITIO MODELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AB INITIO MODELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AB INITIO MODELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOMOLOGY MODELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOMOLOGY MODELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOMOLOGY MODELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MOLECULAR DYNAMICS SIMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MOLECULAR DYNAMICS SIMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MOLECULAR DYNAMICS SIMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CLOUD BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CLOUD BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CLOUD BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HYBRID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HYBRID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HYBRID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ON PREMISES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ON PREMISES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ON PREMISES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. G7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 237. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. NATO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 258. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 266. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 269. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 271. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 277. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 280. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY ADMET & TOXICOLOGY PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIAL OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROTEIN STRUCTURE PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 299. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 302. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARK